Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557913 | 1.00 | IDO1 (0.42) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL1728961 | 1.00 | IDO1 (0.42) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL1876903 | 0.97 | IDO1 (0.45) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL1003419 | 0.97 | IDO1 (0.45) | IDO1TDO2ADRB2CES2CES1 | |
| Hydrochloric Acid SCHEMBL16341078 | 0.97 | IDO1 (0.45) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL25078128 | 0.85 | IDO1 (0.33) | IDO1TDO2ADRB2CES2CES1 | |
| SCHEMBL17041581 | 0.85 | ACHE (0.34) | IDO1TDO2ADRB2PDE2A | |
| SCHEMBL29337278 | 0.85 | ACHE (0.34) | IDO1TDO2ADRB2PDE2A | |
| SCHEMBL1006029 | 0.84 | GBA1 (0.36) | IDO1TDO2ADRB2PDE2AGBA1 | |
| SCHEMBL16649721 | 0.84 | ADRB2 (0.46) | IDO1TDO2ADRB2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-115490699-B | Fused ring compound, pharmaceutical composition and application thereof | 成都海博为药业有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-113271950-B | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269989-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-2036881-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-(FLUORO-, TRIFLUOROMETHYL- OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVE | Central Glass Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7368609-B2 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | NAT1, MAOA, HNMT | IDO1 232/4885TDO2 164/4885ADRB2 415/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | IDO1 4536/4885TDO2 4727/4885ADRB2 397/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | IDO1 362/4885TDO2 262/4885ADRB2 37/4885 |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | IDO1 1179/4885TDO2 2050/4885ADRB2 2719/4885 |
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | IDO1 62/4885TDO2 2950/4885ADRB2 3/4885 |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | IDO1 1754/4885TDO2 4471/4885ADRB2 1258/4885 |
| US-11987597-B2 | Modulators of TNF-α activity | TNF, TNFRSF1A, NFKBIA | IDO1 1679/4885TDO2 4371/4885ADRB2 1337/4885 |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | NAT1, AFF1, PNMT | IDO1 626/4885TDO2 405/4885ADRB2 45/4885 |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | IDO1 1754/4885TDO2 4471/4885ADRB2 1258/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | IDO1 1754/4885TDO2 4471/4885ADRB2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.